GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Aurinia Pharmaceuticals AUPH · USD

Health Care · US listing · 🇺🇸 United States

Compare

16.62

+0.97%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$283.1m

FY2016FY2025

Net income

$287.2m

FY2016FY2025

Free cash flow

$135.4m

FY2016FY2025

Shareholders' equity

$581.3m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$283.1m$235.1m$175.5m$134.0m$45.6m$50.1m$318,000$463,000$420,000$173,000
Research and development$32.5m$20.8m$49.6m$45.0m$51.1m$50.3m$52.9m$41.4m$33.9m$14.5m
Operating income$104.9m−$4.7m−$91.7m−$111.5m−$180.7m−$104.3m−$90.9m−$56.2m−$47.1m−$22.8m
Net income$287.2m$5.8m−$78.0m−$108.2m−$181.0m−$102.7m−$88.4m−$64.1m−$70.8m−$23.3m
Diluted earnings per share2.070.04-0.54-0.76-1.37-0.87-0.90-0.75-0.85-0.41

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$751.6m$550.6m$548.1m$470.9m$543.4m$463.7m$324.3m$145.9m$189.8m$57.0m
Cash and short-term investments$398.0m$358.5m$350.5m$389.4m$466.1m$398.3m$306.0m$125.9m$173.5m$39.6m
Total liabilities$170.3m$173.2m$170.1m$65.4m$64.3m$55.9m$25.7m$33.3m$24.1m$21.0m
Debt$68.8m$72.6m$90.1m———————
Shareholders' equity$581.3m$377.5m$378.0m$405.4m$479.1m$407.8m$298.6m$112.6m$165.7m$36.0m
Shares outstanding139m148m144m142m132m118m98m85m83m57m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$135.7m$44.4m−$33.5m−$79.5m−$157.7m−$69.9m−$63.6m−$51.6m−$41.2m−$18.7m
Capital spending−$252,000−$281,000−$718,000−$292,000−$1.5m−$7.3m−$101,000−$75,000−$25,000−$25,000
Free cash flow$135.4m$44.1m−$34.2m−$79.8m−$159.2m−$77.2m−$63.7m−$51.7m−$41.2m−$18.7m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$83.2m$77.7m$77.1m$73.5m$70.0m$62.5m$59.9m$67.8m
Operating income$46.3m$41.4m$33.2m$29.7m$20.1m$21.8m−$1.7m$11.7m
Net income$37.4m$34.4m$210.8m$31.6m$21.5m$23.3m$1.4m$14.3m
Diluted earnings per share0.280.261.520.230.160.170.010.10
Cash from operations$52.0m$32.0m$44.0m$44.0m$44.0m$1.0m$30.0m$17.0m
Total assets$792.3m$724.0m$751.6m$527.5m$502.6m$504.9m$550.6m$549.4m
Cash and short-term investments$443.1m$378.8m$398.0m$351.8m$315.1m$312.9m$358.5m$348.7m
Debt$16.5m$18.1m$17.6m$17.4m$17.2m$15.5m$15.1m$15.9m
Shareholders' equity$614.9m$567.6m$581.3m$365.8m$335.3m$350.2m$377.5m$388.0m

Financial ratios

Data as of 31 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin41.9%5.2%-42.6%-83.2%-395.1%-208.1%
Net margin101.5%2.4%-44.5%-80.7%-396.8%-204.9%
Return on equity49.4%1.5%-20.6%-26.7%-37.8%-25.2%
Return on assets38.2%1.0%-14.2%-23.0%-33.3%-22.1%
Free cash flow yield5.9%1.8%-1.4%-3.3%-7.1%-3.2%
Revenue growth20.4%34.0%31.0%193.9%-9.0%15660.4%
Earnings growth4893.1%-107.4%-27.9%-40.2%76.2%16.2%
Current ratio5.25x4.57x5.50x9.60x12.63x13.11x
Debt to equity0.03x0.04x0.04x0.00x0.00x0.00x
Equity ratio77.3%68.6%69.0%86.1%88.2%87.9%
Interest coverage27.36x2.54x-26.92x-21.78x-340.65x-19.70x
R&D as a share of sales11.5%8.8%28.3%33.6%112.1%100.4%
Buybacks as a share of market value6.1%-2.7%-1.1%-7.7%-11.5%-21.0%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue28.3%41.4%103.3%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin19.3%-12.4%-42.0%-67.9%
Net margin56.5%12.9%-19.2%-47.8%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings7.7230.6-16.6-5.7-16.7-16.0-22.4-9.1-5.3-5.1
Price to sales7.85.67.44.666.232.7————

Market value over time

30 Nov 2016 to 30 Oct 2026, in USD

$109.4m$2.22bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return75%-4%111%-79%56%-31%242%19%80%154%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 50-to-1 reverse split · 23 Oct 2013

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.